About Matinas BioPharma (NYSEAMERICAN:MTNB)
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-2.94594594594595
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-195.09%
Return on Assets-79.34%
Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions
What is Matinas BioPharma's stock symbol?
Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."
How were Matinas BioPharma's earnings last quarter?
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced its quarterly earnings results on Wednesday, November, 15th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The firm earned $0.05 million during the quarter, compared to analysts' expectations of $0.05 million. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%. View Matinas BioPharma's Earnings History.
When will Matinas BioPharma make its next earnings announcement?
Where is Matinas BioPharma's stock going? Where will Matinas BioPharma's stock price be in 2018?
3 analysts have issued 1 year target prices for Matinas BioPharma's stock. Their forecasts range from $6.00 to $9.00. On average, they anticipate Matinas BioPharma's share price to reach $7.67 in the next twelve months. View Analyst Ratings for Matinas BioPharma.
What are Wall Street analysts saying about Matinas BioPharma stock?
Here are some recent quotes from research analysts about Matinas BioPharma stock:
- 1. Maxim Group analysts commented, "Summary Matinas stock is down sharply today on news that MAT2203’s efficacy in VVC (vulvovaginal candidiasis) fell well below expectations both internal and external, but wait a second…Was it ever supposed to compare?." (6/26/2017)
- 2. Aegis analysts commented, "Matinas reported the results of the Phase I study testing safety, tolerability and pharmacokinetics of MAT2501, its cochleated version of amikacin. This announcement meets the endpoints and time frame we had expected. Separately, we have received inquiries regarding comments posted to a financial website to which we attribute the recent volatility in the stock. We believe these comments are based on incorrect information, and reiterate our Buy rating on the stock." (3/28/2017)
Are investors shorting Matinas BioPharma?
Matinas BioPharma saw a increase in short interest in February. As of February 28th, there was short interest totalling 1,383,862 shares, an increase of 5.0% from the February 15th total of 1,317,968 shares. Based on an average daily volume of 192,420 shares, the short-interest ratio is presently 7.2 days.
Who are some of Matinas BioPharma's key competitors?
Some companies that are related to Matinas BioPharma include Palatin Technologies (PTN), Silence Therapeutics (SLN), Bioventix (BVXP), Asterias Biotherapeutics (AST), Tissue Regenix Group (TRX), Navidea Biopharmaceuticals (NAVB), NovaBay Pharmaceuticals (NBY), Abzena (ABZA), Scancell (SCLP), Can Fite Biopharma (CANF), ReNeuron Group (RENE), Repros Therapeutics (RPRX), Akers Biosciences (AKR), AmpliPhi Biosciences (APHB), Synairgen (SNG), Vernalis (VER), Ixico (IXI) and ImmunoCellular Therapeutics (IMUC).
Who are Matinas BioPharma's key executives?
Matinas BioPharma's management team includes the folowing people:
- Jerome D. Jabbour J.D., President (Age 42)
- Roelof Rongen, Chief Executive Officer, Director (Age 51)
- Gary Gaglione CPA, Vice President of Finance and Accounting and Acting Chief Financial Officer (Age 64)
- Douglas F. Kling, Senior Vice President - Clinical Development (Age 43)
- Abdel A. Fawzy Ph.D., Executive Vice President for Pharmaceutical and Supply Chain Development (Age 66)
- Dominick M. Dipaolo, Senior Vice President - Quality and Regulatory Compliance (Age 41)
- Raphael J. Mannino Ph.D., Chief Scientific Officer (Age 70)
- Herbert J. Conrad, Chairman of the Board (Age 84)
- Eric J. Ende M.D., Director (Age 48)
- Adam K. Stern, Director (Age 53)
Has Matinas BioPharma been receiving favorable news coverage?
Media coverage about MTNB stock has been trending positive this week, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Matinas BioPharma earned a media sentiment score of 0.39 on Accern's scale. They also assigned media headlines about the company an impact score of 45.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Matinas BioPharma's major shareholders?
Matinas BioPharma's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.72%), Alliance Wealth Management Group (0.43%), IFP Advisors Inc (0.27%), Deutsche Bank AG (0.16%), American Century Companies Inc. (0.14%) and Virtu Financial LLC (0.11%). Company insiders that own Matinas BioPharma stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma.
Which institutional investors are selling Matinas BioPharma stock?
Which institutional investors are buying Matinas BioPharma stock?
MTNB stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Deutsche Bank AG, BlackRock Inc. and Virtu Financial LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma.
How do I buy shares of Matinas BioPharma?
Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Matinas BioPharma's stock price today?
One share of MTNB stock can currently be purchased for approximately $1.09.
How big of a company is Matinas BioPharma?
Matinas BioPharma has a market capitalization of $96.67 million.
How can I contact Matinas BioPharma?
Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.
MarketBeat Community Rating for Matinas BioPharma (MTNB)MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Matinas BioPharma (NYSEAMERICAN:MTNB) Earnings History and Estimates Chart
Matinas BioPharma (NYSEAMERICAN MTNB) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/15/2017||Q3 2017||($0.05)||($0.04)||$0.05 million||$0.05 million||View||N/A|
|8/8/2017||Q2 2017||($0.05)||($0.04)||$0.02 million||$0.05 million||View||Listen|
|5/16/2017||Q1 2017||($0.04)||($0.25)||$0.02 million||View||N/A|
|11/10/2015||Q3 2016||($0.03)||($0.11)||$0.10 million||$0.06 million||View||N/A|
|8/13/2015||Q2 2015||($0.05)||($0.04)||$0.10 million||$0.08 million||View||N/A|
|5/11/2015||Q1 2015||($0.08)||($0.07)||$0.06 million||View||N/A|
Matinas BioPharma (NYSEAMERICAN:MTNB) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Matinas BioPharma (NYSEAMERICAN:MTNB)
No dividend announcements for this company have been tracked by MarketBeat.com
Matinas BioPharma (NYSEAMERICAN MTNB) Insider Trading and Institutional Ownership History
Matinas BioPharma (NYSEAMERICAN MTNB) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|9/8/2017||Adam K Stern||Director||Buy||100,000||$1.38||$138,000.00||793,992|| |
|9/8/2017||Roelof Rongen||CEO||Buy||5,000||$1.36||$6,800.00||3,539,416|| |
|9/7/2017||James S Scibetta||Director||Buy||5,000||$1.29||$6,450.00||418,309|| |
Matinas BioPharma (NYSEAMERICAN MTNB) News Headlines
Matinas BioPharma (NYSEAMERICAN:MTNB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Matinas BioPharma (NYSEAMERICAN MTNB) Stock Chart for Wednesday, March, 21, 2018